Document:

Exhibit 10.1

 

NeuBase
Therapeutics, Inc.

 

OUTSIDE
DIRECTOR COMPENSATION POLICY

 

Most Recently Amended Effective as of September
8, 2022

 

NeuBase Therapeutics, Inc.
(the “Company”) believes that the granting of equity and cash compensation to its members of the Board
of Directors (the “Board,” and members of the Board, the “Directors”) represents
an effective tool to attract, retain and reward Directors who are not employees of the Company (the “Outside Directors”).
This Outside Director Compensation Policy (the “Policy”) is intended to formalize the Company’s policy
regarding cash compensation and grants of equity to its Outside Directors. Unless otherwise defined herein, capitalized terms used in
this Policy will have the meaning given such term in the Company’s 2019 Stock Incentive Plan, as amended (as may be amended or restated
from time to time, the “Plan”). Each Outside Director will be solely responsible for any tax obligations incurred
by such Outside Director as a result of the equity and cash payments such Outside Director receives under this Policy.

 

		1.	Retainers
Effective as of October 1, 2020

 

BOARD
MEMBERSHIP

 

	Outside Directors:	 	$	35,000	 	 	Annual Retainer
	Lead Independent Director:	 	$	20,0001	 	 	Annual Retainer

 

AUDIT
COMMITTEE

 

Annual
compensation for Audit Committee members is as follows:

 

	Chairperson
    of Committee:	 	$	15,000	 	 	Annual
    Retainer
	Committee
    Members (other than Chairperson)	 	$	7,500	 	 	Annual
    Retainer

 

COMPENSATION
COMMITTEE

 

Annual
compensation for the Compensation Committee is as follows:

 

	Chairperson
    of Committee:	 	$	10,000	 	 	Annual
    Retainer
	Committee
    Members (other than Chairperson)	 	$	5,000	 	 	Annual
    Retainer

 

NOMINATING
 & CORPORATE GOVERNANCE COMMITTEE

 

Compensation
for the Nominating & Corporate Committee is as follows:

 

	Chairperson
    of Committee:	 	$	8,000	 	 	Annual
    Retainer
	Committee
    Members (other than Chairperson):	 	$	4,000	 	 	Annual
    Retainer

 

There
are no per meeting attendance fees for attending Board, Audit Committee, Compensation Committee or Nominating & Corporate
Governance Committee meetings.

 

Retainers will be paid quarterly
in arrears on a prorated basis.

 

 

1
In addition to the “Outside Directors” fee noted immediately above.

 

     

     

    

 

		2.	Equity
Compensation

 

Outside Directors will be
entitled to receive all types of Awards (except Incentive Stock Options) under the Plan (or the applicable equity plan in place at
the time of grant), including discretionary Awards not covered under this Policy. All grants of Awards to Outside Directors pursuant to
Section 2 of this Policy will be automatic and nondiscretionary, except as otherwise provided herein, and will be made in accordance
with the following provisions:

 

(a)               
Appointment Awards. Subject to Section 5.03 of the Plan, upon an Outside Director’s appointment to the Board, such
Outside Director automatically will be granted a Nonstatutory Stock Option (I) to purchase that number of shares of Company common stock
(the “Shares”) equal to 0.24% of the Company’s outstanding shares of voting capital stock as of the close
of business on the effective date of such Outside Director’s appointment, rounded down to the nearest whole share, or (II) with
a grant date fair value of $180,000, rounded down to the nearest whole Share, whichever of clause (I) and (II) above covers the lowest
number of Shares (the “NSO Appointment Award”). Subject to Section 5 below and Article XII of the Plan, 25%
of each NSO Appointment Award will vest on the one-year anniversary of the grant date, and the remaining Shares subject to the NSO Appointment
Award shall vest on an equal monthly basis over the following 36 months, provided that the Outside Director is in continuous service
with the Company or an Affiliate through the applicable vesting date. Each NSO Appointment Award will vest fully upon a Change in Control
(as defined in the Plan), in each case, provided that the Outside Director is in continuous service with the Company or an Affiliate
through the Change in Control.

 

(b)       Annual
Awards. Subject to Section 5.03 of the Plan, on the first business day after each Annual Meeting of the Company’s stockholders
(the “Annual Meeting”) beginning with the 2022 Annual Meeting, each Outside Director automatically will be granted
a Nonstatutory Stock Option, subject to Section 5 below, (I) to purchase that number of Shares equal to 0.12% of the Company’s outstanding
shares of voting capital stock as of the close of business on the date of such Annual Meeting, rounded down to the nearest whole share,
or (II) with a grant date fair value of $90,000, rounded down to the nearest whole Share, whichever of clause (I) and (II) above covers
the lowest number of Shares (the “Annual NSO Award”). Subject to Section 5 below and Article XII of the Plan,
25% of each Annual NSO Award will vest on the one-year anniversary of the grant date, and the remaining Shares subject to the Annual NSO
Award shall vest on an equal monthly basis over the following 36 months, provided that the Outside Director is in continuous service
with the Company or an Affiliate through the applicable vesting date. Each Annual NSO Award will vest fully upon a Change in Control (as
defined in the Plan), in each case, provided that the Outside Director is in continuous service with the Company or an Affiliate
through the Change in Control.

 

(c)       Individual
Limit. Notwithstanding anything in this Policy to the contrary, in no event will any Outside Director be granted one or more Awards
in any calendar year that exceed the maximum Award limitations applicable to Outside Directors set forth in the Plan.

 

(d)       Terms
Applicable to all Options Granted Under this Policy. The per Share exercise price for all other Options granted under this Policy
will be one hundred percent (100%) of the Fair Market Value on the grant date.

 

		3.	Travel
Expenses

 

Each Outside Director’s
reasonable, customary and documented travel expenses to Board meetings will be reimbursed by the Company.

 

    2

     

    

 

		4.	Additional
Provisions

 

All provisions of the Plan
not inconsistent with this Policy will apply to Awards granted to Outside Directors.

 

		5.	Adjustments

 

In
the event that any dividend or other distribution (whether in the form of cash, Shares, other securities or other property), recapitalization,
stock split, reverse stock split, reorganization, merger, consolidation, split-up, spin-off, combination, repurchase, or exchange of
Shares or other securities of the Company or other change in the corporate structure of the Company affecting the Shares occurs, the
Administrator, in order to prevent diminution or enlargement of the benefits or potential benefits intended to be made available under
this Policy, will adjust the number of Shares issuable pursuant to Awards granted under this Policy.

 

		6.	Revisions

 

Each of the Board and the
Committee, in its discretion, may change and otherwise revise the terms of Awards granted under this Policy, including, without limitation,
the number of Shares subject thereto, for Awards of the same or different type granted on or after the date the Board or the Committee
determines to make any such change or revision.

 

    3Exhibit
4.1

 

FORM
OF COMMON SHARE PURCHASE WARRANT

 

altamira
therapeutics LTD.

 

	Warrant Shares: _______	Issue Date: September 9, 2022

 

THIS
COMMON SHARE PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the
“Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set
forth, at any time on or after October 1, 2022 (the “Initial Exercise Date”) and on or prior to the close of business
on September 30, 2027 (the “Termination Date”) but not thereafter, to subscribe for and purchase from Altamira Therapeutics
Ltd., an exempted company limited by shares incorporated in Bermuda (the “Company”), up to ______ registered common
shares, par value CHF 0.01 per share (each, a “Common Share”) (as subject to adjustment hereunder, the “Warrant
Shares”). The purchase price of one Common Share under this Warrant shall be equal to the Exercise Price, as defined in Section
2(b).

 

	1	Definitions.

 

In addition to the terms defined elsewhere in
this Warrant, the following terms have the meanings indicated in this Section 1:

 

“Affiliate”
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control
with a Person, as such terms are used in and construed under Rule 405 under the Securities Act.

 

“Business
Day” means any day except any Saturday, any Sunday, any day which is a federal legal holiday in the United States or any day
on which banking institutions in the State of New York are authorized or required by law or other governmental action to close.

 

“Commission”
means the United States Securities and Exchange Commission.

 

“Common
Share Equivalents” means any securities of the Company or its subsidiaries which would entitle the holder thereof to acquire
at any time Common Shares, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument that
is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Shares.

 

“Exchange
Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.

 

     

     

    

 

“Market
Price” of a Common Share on any date shall mean the arithmetic mean of the VWAP on each of the five (5) consecutive Trading
Days immediately preceding such date. The Market Price shall be appropriately adjusted for any stock dividend, stock split, stock combination
or other similar transaction during such period.

 

“Person”
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability
company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.

 

“Securities
Act” means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.

 

“Trading
Day” means a day on which the principal Trading Market is open for trading.

 

“Trading
Market” means any of the following markets or exchanges on which the Common Shares are listed or quoted for trading on the
date in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, the New York
Stock Exchange, OTCQB or OTCQX (or any successors to any of the foregoing).

 

“Transfer Agent”
means American Stock Transfer & Trust Company, LLC, the current transfer agent for the Company, with a mailing address of 48 Wall
Street, 22nd Floor, New York, NY 10005 and a facsimile number of (718) 234-5001, and any successor transfer agent of the Company.

 

“Warrants”
means this Warrant and other Common Share purchase warrants issued with identical terms hereto by the Company pursuant to Loan Agreement
dated September 9, 2022, between the Company and the Lenders.

 

	2	Exercise.

 

		a)	Exercise of Warrant.
                                            Exercise of the purchase rights represented by this Warrant may be made, in whole or in part,
                                            at any time or times on or after the Initial Exercise Date and on or before 5:00 p.m. (Zurich
                                            time) on the Termination Date by delivery to the Company of a duly executed facsimile copy
                                            (or pdf copy via e-mail attachment) of the Notice of Exercise in the form annexed hereto
                                            (the “Notice of Exercise”). Within the earlier of (i) two (2) Trading
                                            Days and (ii) the number of Trading Days comprising the Standard Settlement Period (as defined
                                            in Section 2(d)(i) herein) following the date of exercise as aforesaid, the Holder shall
                                            deliver the aggregate Exercise Price for the Warrant Shares specified in the applicable Notice
                                            of Exercise by wire transfer unless the cashless exercise procedure specified in Section
                                            2(c) below is specified in the applicable Notice of Exercise. No ink-original Notice of Exercise
                                            shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization)
                                            of any Notice of Exercise be required. Notwithstanding anything herein to the contrary, the
                                            Holder shall not be required to physically surrender this Warrant to the Company until the
                                            Holder has purchased all of the Warrant Shares available hereunder and the Warrant has been
                                            exercised in full, in which case, the Holder shall surrender this Warrant to the Company
                                            for cancellation within three (3) Trading Days of the date on which the final Notice of Exercise
                                            is delivered to the Company. Partial exercises of this Warrant resulting in purchases of
                                            a portion of the total number of Warrant Shares available hereunder shall have the effect
                                            of lowering the outstanding number of Warrant Shares purchasable hereunder in an amount equal
                                            to the applicable number of Warrant Shares purchased. The Holder and the Company shall maintain
                                            records showing the number of Warrant Shares purchased and the date of such purchases. The
                                            Company shall deliver any objection to any Notice of Exercise within one (1) Business Day
                                            of receipt of such notice. The Holder and any assignee, by acceptance of this Warrant, acknowledge
                                            and agree that, by reason of the provisions of this paragraph, following the purchase of
                                            a portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase
                                            hereunder at any given time may be less than the amount stated on the face hereof.

 

    2

     

    

 

Notwithstanding
the foregoing in this Section 2(a), a holder whose interest in this Warrant is a beneficial interest in certificate(s) representing this
Warrant held in book-entry form through DTC (or another established clearing corporation performing similar functions), shall effect
exercises made pursuant to this Section 2(a) by delivering to DTC (or such other clearing corporation, as applicable) the appropriate
instruction form for exercise, complying with the procedures to effect exercise that are required by DTC (or such other clearing corporation,
as applicable).

 

		b)	Exercise Price. The exercise price per Common Share under
                                            this Warrant shall be CHF 0.xx, subject to adjustment hereunder (the “Exercise Price”).
                                            In no event shall the Exercise Price be adjusted below the par value (or U.S. dollar equivalent)
                                            of the Common Shares, which is CHF 0.01 per share as of the Initial Exercise Date.

 

		c)	Cashless Exercise. If 60 days after the Initial Exercise Date,
                                            there is no effective registration statement registering, or no current prospectus available
                                            for, the issuance of the Warrant Shares to the Holder, then this Warrant may also be exercised,
                                            in whole or in part, at such time by means of a “cashless exercise” in which
                                            the Holder shall be entitled to receive a number of Warrant Shares equal to the quotient
                                            obtained by dividing [(A-B) (X)] by (A), where:

 

(A) = as applicable: (i)
the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise if such Notice of Exercise is (1) both
executed and delivered pursuant to Section 2(a) hereof on a day that is not a Trading Day or (2) both executed and delivered pursuant
to Section 2(a) hereof on a Trading Day prior to the opening of “regular trading hours” (as defined in Rule 600(b)(64) of
Regulation NMS promulgated under the federal securities laws) on such Trading Day, (ii) at the option of the Holder, either (y) the VWAP
on the Trading Day immediately preceding the date of the applicable Notice of Exercise or (z) the Bid Price of the Common Shares on the
principal Trading Market as reported by Bloomberg L.P. as of the time of the Holder’s execution of the applicable Notice of Exercise
if such Notice of Exercise is executed during “regular trading hours” on a Trading Day and is delivered within two (2) hours
thereafter (including until two (2) hours after the close of “regular trading hours” on a Trading Day) pursuant to Section
2(a) hereof or (iii) the VWAP on the date of the applicable Notice of Exercise if the date of such Notice of Exercise is a Trading Day
and such Notice of Exercise is both executed and delivered pursuant to Section 2(a) hereof after the close of “regular trading
hours” on such Trading Day;

 

    3

     

    

 

(B) = the Exercise Price
of this Warrant, as adjusted hereunder; and

 

(X) = the number of Warrant
Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant if such exercise were by means
of a cash exercise rather than a cashless exercise.

 

If
Warrant Shares are issued in such a “cashless exercise,” the parties acknowledge and agree that in accordance with Section
3(a)(9) of the Securities Act, the Warrant Shares shall take on the registered characteristics of the Warrants being exercised. The Company
agrees not to take any position contrary to this Section 2(c).

 

“Bid
Price” means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Shares
are then listed or quoted on a Trading Market, the bid price of the Common Shares for the time in question (or the nearest preceding
date) on the Trading Market on which the Common Shares are then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day
from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted
average price of the Common Shares for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Shares
are not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Shares are then reported in the “Pink
Sheets” published by OTC Markets Group, Inc. (or a similar organization or agency succeeding to its functions of reporting prices),
the most recent bid price per Common Share so reported, or (d) in all other cases, the fair market value of a Common Share as determined
by an independent appraiser selected in good faith by the Holders of a majority in interest of the Warrants then outstanding and reasonably
acceptable to the Company, the fees and expenses of which shall be paid by the Company.

 

“VWAP”
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Shares are then listed
or quoted on a Trading Market, the daily volume weighted average price of the Common Shares for such date (or the nearest preceding date)
on the Trading Market on which the Common Shares are then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from
9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted
average price of the Common Shares for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Shares
are not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Shares are then reported in the “Pink
Sheets” published by OTC Markets Group, Inc. (or a similar organization or agency succeeding to its functions of reporting prices),
the most recent bid price per Common Share so reported, or (d) in all other cases, the fair market value of a Common Share as determined
by an independent appraiser selected in good faith by the Holders of a majority in interest of the Warrants then outstanding and reasonably
acceptable to the Company, the fees and expenses of which shall be paid by the Company.

 

    4

     

    

 

Notwithstanding
anything herein to the contrary, on the Termination Date, this Warrant shall be automatically exercised via cashless exercise pursuant
to this Section 2(c).

 

		d)	Mechanics of Exercise.

 

		i.	Delivery of Warrant Shares Upon Exercise. The Company shall
                                            cause the Warrant Shares purchased hereunder to be transmitted by the Transfer Agent to the
                                            Holder by crediting the account of the Holder’s or its designee’s balance account
                                            with The Depository Trust Company through its Deposit or Withdrawal at Custodian system (“DWAC”)
                                            if the Company is then a participant in such system and either (A) there is an effective
                                            registration statement permitting the issuance of the Warrant Shares to or resale of the
                                            Warrant Shares by Holder or (B) this Warrant is being exercised via cashless exercise, and
                                            otherwise by physical delivery of a certificate, registered in the Company’s share
                                            register in the name of the Holder or its designee, for the number of Warrant Shares to which
                                            the Holder is entitled pursuant to such exercise to the address specified by the Holder in
                                            the Notice of Exercise by the date that is the earlier of (i) two (2) Trading Days and (ii)
                                            the number of Trading Days comprising the Standard Settlement Period after the delivery to
                                            the Company of the Notice of Exercise (such date, the “Warrant Share Delivery Date”).
                                            Upon delivery of the Notice of Exercise, the Holder shall be deemed for all corporate purposes
                                            to have become the holder of record of the Warrant Shares with respect to which this Warrant
                                            has been exercised, irrespective of the date of delivery of the Warrant Shares, and for purposes
                                            of Regulation SHO, a holder whose interest in this Warrant is a beneficial interest in certificate(s)
                                            representing this Warrant held in book-entry form through DTC shall be deemed to have exercised
                                            its interest in this Warrant upon instructing its broker that is a DTC participant to exercise
                                            its interest in this Warrant, provided that in each such case payment of the aggregate Exercise
                                            Price (other than in the case of a cashless exercise) is received within the earlier of (i)
                                            two (2) Trading Days and (ii) the number of Trading Days comprising the Standard Settlement
                                            Period following delivery of the Notice of Exercise. If the Company fails for any reason
                                            to deliver to the Holder the Warrant Shares subject to a Notice of Exercise by the Warrant
                                            Share Delivery Date, the Company shall pay to the Holder, in cash, as liquidated damages
                                            and not as a penalty, for each $1,000 of Warrant Shares subject to such exercise (based on
                                            the VWAP of the Common Shares on the date of the applicable Notice of Exercise), $10 per
                                            Trading Day (increasing to $20 per Trading Day on the fifth Trading Day after such liquidated
                                            damages begin to accrue) for each Trading Day after such Warrant Share Delivery Date until
                                            such Warrant Shares are delivered or Holder rescinds such exercise. The Company agrees to
                                            maintain a transfer agent that is a participant in the FAST program so long as this Warrant
                                            remains outstanding and exercisable. As used herein, “Standard Settlement Period”
                                            means the standard settlement period, expressed in a number of Trading Days, on the Company’s
                                            primary Trading Market with respect to the Common Shares as in effect on the date of delivery
                                            of the Notice of Exercise. Notwithstanding the foregoing, with respect to any Notice(s) of
                                            Exercise delivered by 12:00 p.m. (New York City time) on the Initial Exercise Date, which
                                            Notice of Exercise(s) may be delivered at any time after the time of execution of the Loan
                                            Agreement dated September 9, 2022, between the Company and the Lenders, the Company agrees
                                            to deliver the Warrant Shares subject to such notice(s) by 4:00 p.m. (New York City time)
                                            on the Initial Exercise Date and the Initial Exercise Date shall be the Warrant Share Delivery
                                            Date for purposes hereunder.

 

    5

     

    

 

		ii.	Delivery of New Warrants Upon Exercise. If this Warrant shall
                                            have been exercised in part, the Company shall, at the request of a Holder and upon surrender
                                            of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the
                                            Holder a new Warrant evidencing the rights of the Holder to purchase the unpurchased Warrant
                                            Shares called for by this Warrant, which new Warrant shall in all other respects be identical
                                            with this Warrant.

 

		iii.	Rescission Rights. If the Company fails to cause the Transfer
                                            Agent to transmit to the Holder the Warrant Shares pursuant to Section 2(d)(i) by the Warrant
                                            Share Delivery Date, then the Holder will have the right to rescind such exercise.

 

		iv.	Compensation for Buy-In on Failure to Timely Deliver Warrant
                                            Shares Upon Exercise. In addition to any other rights available to the Holder, if the
                                            Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in
                                            accordance with the provisions of Section 2(d)(i) above pursuant to an exercise on or before
                                            the Warrant Share Delivery Date, and if after such date the Holder is required by its broker
                                            to purchase (in an open market transaction or otherwise) or the Holder’s brokerage
                                            firm otherwise purchases, Common Shares to deliver in satisfaction of a sale by the Holder
                                            of the Warrant Shares which the Holder anticipated receiving upon such exercise (a “Buy-In”),
                                            then the Company shall (A) pay in cash to the Holder the amount, if any, by which (x) the
                                            Holder’s total purchase price (including brokerage commissions, if any) for the Common
                                            Shares so purchased exceeds (y) the amount obtained by multiplying (1) the number of Warrant
                                            Shares that the Company was required to deliver to the Holder in connection with the exercise
                                            at issue times (2) the price at which the sell order giving rise to such purchase obligation
                                            was executed (without deducting brokerage commissions, if any), and (B) at the option of
                                            the Holder, either reinstate the portion of the Warrant and equivalent number of Warrant
                                            Shares for which such exercise was not honored (in which case such exercise shall be deemed
                                            rescinded) or deliver to the Holder the number of Common Shares that would have been issued
                                            had the Company timely complied with its exercise and delivery obligations hereunder. For
                                            example, if the Holder purchases Common Shares having a total purchase price of CHF 11,000
                                            to cover a Buy-In with respect to an attempted exercise of Common Shares with an aggregate
                                            sale price giving rise to such purchase obligation of CHF 10,000, under clause (A) of the
                                            immediately preceding sentence the Company shall be required to pay the Holder CHF 1,000.
                                            The Holder shall provide the Company written notice indicating the amounts payable to the
                                            Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount
                                            of such loss. Nothing herein shall limit a Holder’s right to pursue any other remedies
                                            available to it hereunder, at law or in equity including, without limitation, a decree of
                                            specific performance and/or injunctive relief with respect to the Company’s failure
                                            to timely deliver Common Shares upon exercise of the Warrant as required pursuant to the
                                            terms hereof.

 

    6

     

    

 

		v.	No Fractional Shares or Scrip. No fractional shares or scrip
                                            representing fractional shares shall be issued upon the exercise of this Warrant. As to any
                                            fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise,
                                            the Company shall, at its election, either pay a cash adjustment in respect of such final
                                            fraction in an amount equal to such fraction multiplied by the Exercise Price or round up
                                            to the next whole share.

 

		vi.	Charges, Taxes and Expenses. Issuance of Warrant Shares shall
                                            be made without charge to the Holder for any issue or transfer tax or other incidental expense
                                            in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall
                                            be paid by the Company, and such Warrant Shares shall be issued in the name of the Holder
                                            or in such name or names as may be directed by the Holder; provided, however, that in the
                                            event that Warrant Shares are to be issued in a name other than the name of the Holder, this
                                            Warrant when surrendered for exercise shall be accompanied by the Assignment Form attached
                                            hereto as Exhibit B duly executed by the Holder and the Company may require, as a condition
                                            thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental
                                            thereto. The Company shall pay all Transfer Agent fees required for same-day processing of
                                            any Notice of Exercise and all fees to the Depository Trust Company (or another established
                                            clearing corporation performing similar functions) required for same-day electronic delivery
                                            of the Warrant Shares.

 

		vii.	Closing of Books. The Company will not close its shareholder
                                            books or records in any manner which prevents the timely exercise of this Warrant, pursuant
                                            to the terms hereof.

 

		e)	Holder’s Exercise Limitations. The Company shall not
                                            effect any exercise of this Warrant, and a Holder shall not have the right to exercise any
                                            portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving
                                            effect to such issuance after exercise as set forth on the applicable Notice of Exercise,
                                            the Holder (together with the Holder’s Affiliates, and any other Persons acting as
                                            a group together with the Holder or any of the Holder’s Affiliates (such Persons, “Attribution
                                            Parties”)), would beneficially own in excess of the Beneficial Ownership Limitation
                                            (as defined below). For purposes of the foregoing sentence, the number of Common Shares beneficially
                                            owned by the Holder and its Affiliates and Attribution Parties shall include the number of
                                            Common Shares issuable upon exercise of this Warrant with respect to which such determination
                                            is being made, but shall exclude the number of Common Shares which would be issuable upon
                                            (i) exercise of the remaining, nonexercised portion of this Warrant beneficially owned by
                                            the Holder or any of its Affiliates or Attribution Parties and (ii) exercise or conversion
                                            of the unexercised or nonconverted portion of any other securities of the Company (including,
                                            without limitation, any other Common Share Equivalents) subject to a limitation on conversion
                                            or exercise analogous to the limitation contained herein beneficially owned by the Holder
                                            or any of its Affiliates or Attribution Parties. Except as set forth in the preceding sentence,
                                            for purposes of this Section 2(e), beneficial ownership shall be calculated in accordance
                                            with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder,
                                            it being acknowledged by the Holder that the Company is not representing to the Holder that
                                            such calculation is in compliance with Section 13(d) of the Exchange Act and the Holder is
                                            solely responsible for any schedules required to be filed in accordance therewith. To the
                                            extent that the limitation contained in this Section 2(e) applies, the determination of whether
                                            this Warrant is exercisable (in relation to other securities owned by the Holder together
                                            with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable
                                            shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise
                                            shall be deemed to be the Holder’s determination of whether this Warrant is exercisable
                                            (in relation to other securities owned by the Holder together with any Affiliates and Attribution
                                            Parties) and of which portion of this Warrant is exercisable, in each case subject to the
                                            Beneficial Ownership Limitation, and the Company shall have no obligation to verify or confirm
                                            the accuracy of such determination. In addition, a determination as to any group status as
                                            contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act
                                            and the rules and regulations promulgated thereunder. For purposes of this Section 2(e),
                                            in determining the number of outstanding Common Shares, a Holder may rely on the number of
                                            outstanding Common Shares as reflected in (A) the Company’s most recent periodic or
                                            annual report filed with the Commission, as the case may be, (B) a more recent public announcement
                                            by the Company or (C) a more recent written notice by the Company or the Transfer Agent setting
                                            forth the number of Common Shares outstanding. Upon the written or oral request of a Holder,
                                            the Company shall within one (1) Trading Day confirm orally and in writing to the Holder
                                            the number of Common Shares then outstanding. In any case, the number of outstanding Common
                                            Shares shall be determined after giving effect to the conversion or exercise of securities
                                            of the Company, including this Warrant, by the Holder or its Affiliates or Attribution Parties
                                            since the date as of which such number of outstanding Common Shares was reported. The “Beneficial
                                            Ownership Limitation” shall be 4.99% (or, upon election by a Holder prior to the
                                            issuance of any Warrants, 9.99%) of the number of Common Shares outstanding immediately after
                                            giving effect to the issuance of Common Shares issuable upon exercise of this Warrant. The
                                            Holder, upon notice to the Company, may increase or decrease the Beneficial Ownership Limitation
                                            provisions of this Section 2(e), provided that the Beneficial Ownership Limitation in no
                                            event exceeds 9.99% of the number of Common Shares outstanding immediately after giving effect
                                            to the issuance of Common Shares upon exercise of this Warrant held by the Holder and the
                                            provisions of this Section 2(e) shall continue to apply. Any increase in the Beneficial Ownership
                                            Limitation will not be effective until the 61st day after such notice is delivered to the
                                            Company. The provisions of this paragraph shall be construed and implemented in a manner
                                            otherwise than in strict conformity with the terms of this Section 2(e) to correct this paragraph
                                            (or any portion hereof) which may be defective or inconsistent with the intended Beneficial
                                            Ownership Limitation herein contained or to make changes or supplements necessary or desirable
                                            to properly give effect to such limitation. The limitations contained in this paragraph shall
                                            apply to a successor holder of this Warrant.

 

    7

     

    

 

	3	Certain Adjustments.

 

		a)	Share Dividends and Splits. If the Company, at any time while
                                            this Warrant is outstanding: (i) pays a share dividend or otherwise makes a distribution
                                            or distributions on its Common Shares or any other equity or equity equivalent securities
                                            payable in Common Shares (which, for avoidance of doubt, shall not include any Common Shares
                                            issued by the Company upon exercise of this Warrant), (ii) subdivides outstanding Common
                                            Shares into a larger number of shares, (iii) combines (including by way of reverse share
                                            split) outstanding Common Shares into a smaller number of shares or (iv) issues by reclassification
                                            of Common Shares any shares of capital share of the Company, then in each case the Exercise
                                            Price shall be multiplied by a fraction of which the numerator shall be the number of Common
                                            Shares (excluding treasury shares, if any) outstanding immediately before such event and
                                            of which the denominator shall be the number of Common Shares outstanding immediately after
                                            such event, and the number of Warrant Shares issuable upon exercise of this Warrant shall
                                            be proportionately adjusted such that the aggregate Exercise Price of this Warrant shall
                                            remain unchanged. Any adjustment made pursuant to this Section 3(a) shall become effective
                                            immediately after the record date for the determination of shareholders entitled to receive
                                            such dividend or distribution and shall become effective immediately after the effective
                                            date in the case of a subdivision, combination or re-classification.

 

		b)	Subsequent Rights
                                            Offerings. In addition to any adjustments pursuant to Section 3(a) above, if at any time
                                            the Company grants, issues or sells any Common Share Equivalents or rights to purchase stock,
                                            warrants, securities or other property pro rata to the record holders of any class of Common
                                            Shares (the “Purchase Rights”), then the Holder will be entitled to acquire,
                                            upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the
                                            Holder could have acquired if the Holder had held the number of Common Shares acquirable
                                            upon complete exercise of this Warrant (without regard to any limitations on exercise hereof,
                                            including without limitation, the Beneficial Ownership Limitation) immediately before the
                                            date on which a record is taken for the grant, issuance or sale of such Purchase Rights,
                                            or, if no such record is taken, the date as of which the record holders of Common Shares
                                            are to be determined for the grant, issue or sale of such Purchase Rights (provided, however,
                                            that to the extent that the Holder’s right to participate in any such Purchase Right
                                            would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder
                                            shall not be entitled to participate in such Purchase Right to such extent (or beneficial
                                            ownership of such Common Shares as a result of such Purchase Right to such extent) and such
                                            Purchase Right to such extent shall be held in abeyance for the Holder until such time, if
                                            ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership
                                            Limitation).

 

		c)	Cash Dividends.
                                            During such time as this Warrant is outstanding, if the Company shall declare or make
                                            any cash dividend or other cash distribution to holders of Common Shares (a “Cash Dividend”),
                                            at any time after the issuance of this Warrant, then (i) any Exercise Price in effect immediately
                                            prior to the close of business on the record date fixed for the determination of holders
                                            of Common Shares entitled to receive the Cash Dividend shall be reduced, effective as of
                                            the close of business on such record date, to a price determined by multiplying such Exercise
                                            Price by a fraction of which (A) the numerator shall be the Market Price of the Common Shares
                                            on the Trading Day immediately preceding such record date minus the amount of the Cash Dividend
                                            applicable to one Common Share, and (B) the denominator shall be the Market Price of the
                                            Common Shares on the Trading Day immediately preceding such record date; and (ii) the number
                                            of Warrant Shares shall be increased to a number of Common Shares equal to the number of
                                            Common Shares obtainable immediately prior to the close of business on the record date fixed
                                            for the determination of holders of Common Shares entitled to receive the Cash Dividend multiplied
                                            by the reciprocal of the fraction set forth in the immediately preceding clause (i).

 

    8

     

    

 

		d)	Fundamental Transaction.
                                            If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly,
                                            in one or more related transactions effects any merger or consolidation of the Company with
                                            or into another Person, (ii) the Company, directly or indirectly, effects any sale, lease,
                                            license, assignment, transfer, conveyance or other disposition of all or substantially all
                                            of its assets in one or a series of related transactions, (iii) any, direct or indirect,
                                            purchase offer, tender offer or exchange offer (whether by the Company or another Person)
                                            is completed pursuant to which holders of Common Shares are permitted to sell, tender or
                                            exchange their shares for other securities, cash or property and has been accepted by the
                                            holders of 50% or more of the outstanding Common Shares, (iv) the Company, directly or indirectly,
                                            in one or more related transactions effects any reclassification, reorganization or recapitalization
                                            of the Common Shares or any compulsory share exchange pursuant to which the Common Shares
                                            are effectively converted into or exchanged for other securities, cash or property, or (v)
                                            the Company, directly or indirectly, in one or more related transactions consummates a stock
                                            or share purchase agreement or other business combination (including, without limitation,
                                            a reorganization, recapitalization, spin-off or scheme of arrangement) with another Person
                                            or group of Persons whereby such other Person or group acquires more than 50% of the outstanding
                                            Common Shares (not including any Common Shares held by the other Person or other Persons
                                            making or party to, or associated or affiliated with the other Persons making or party to,
                                            such stock or share purchase agreement or other business combination) (each a “Fundamental
                                            Transaction”), then, upon any subsequent exercise of this Warrant, the Holder shall
                                            have the right to receive, for each Warrant Share that would have been issuable upon such
                                            exercise immediately prior to the occurrence of such Fundamental Transaction, at the option
                                            of the Holder (without regard to any limitation in Section 2(e) on the exercise of this Warrant),
                                            the number of Common Shares of the successor or acquiring corporation or of the Company,
                                            if it is the surviving corporation, and any additional consideration (the “Alternate
                                            Consideration”) receivable as a result of such Fundamental Transaction by a holder
                                            of the number of Common Shares for which this Warrant is exercisable immediately prior to
                                            such Fundamental Transaction (without regard to any limitation in Section 2(e) on the exercise
                                            of this Warrant). For purposes of any such exercise, the determination of the Exercise Price
                                            shall be appropriately adjusted to apply to such Alternate Consideration based on the amount
                                            of Alternate Consideration issuable in respect of one Common Share in such Fundamental Transaction,
                                            and the Company shall apportion the Exercise Price among the Alternate Consideration in a
                                            reasonable manner reflecting the relative value of any different components of the Alternate
                                            Consideration. If holders of Common Shares are given any choice as to the securities, cash
                                            or property to be received in a Fundamental Transaction, then the Holder shall be given the
                                            same choice as to the Alternate Consideration it receives upon any exercise of this Warrant
                                            following such Fundamental Transaction. Notwithstanding anything to the contrary, in the
                                            event of a Fundamental Transaction (other than a Fundamental Transaction, under clause (i)
                                            of the definition of Fundamental Transaction, resulting only from the merger of the Company
                                            with a wholly-owned subsidiary of the Company in which the Common Shares remain listed or
                                            quoted on a Trading Market and carry the same economic rights as before such Fundamental
                                            Transaction, and as a result of which the surviving entity has the same assets and liabilities
                                            as the Company before such Fundamental Transaction, but excluding any “reverse merger”
                                            transaction between the Company, a wholly-owned subsidiary of the Company and any other Person,
                                            directly or indirectly, and any merger of the Company with a wholly-owned subsidiary that
                                            follows, within 12 months, such subsidiary entering into any merger or consolidation with
                                            any other Person, directly or indirectly), the Company or any Successor Entity (as defined
                                            below) shall, at the Holder’s option, exercisable at any time concurrently with, or
                                            within 30 days after, the consummation of such Fundamental Transaction (or, if later, the
                                            date of the public announcement of the applicable Fundamental Transaction), purchase this
                                            Warrant from the Holder by paying to the Holder an amount of cash equal to the Black Scholes
                                            Value of the remaining unexercised portion of this Warrant on the date of the consummation
                                            of such Fundamental Transaction. provided, however, if the Fundamental Transaction is not
                                            within the Company’s control, including not approved by the Company’s Board of
                                            Directors, Holder shall only be entitled to receive from the Company or any Successor Entity,
                                            as of the date of consummation of such Fundamental Transaction, the same type or form of
                                            consideration (and in the same proportion), at the Black Scholes Value (as defined below)
                                            of the unexercised portion of this Warrant, that is being offered and paid to the holders
                                            of Common Stock of the Company in connection with the Fundamental Transaction, whether that
                                            consideration be in the form of cash, stock or any combination thereof, or whether the holders
                                            of Common Stock are given the choice to receive from among alternative forms of consideration
                                            in connection with the Fundamental Transaction. “Black Scholes Value”
                                            means the value of this Warrant based on the Black Scholes Option Pricing Model obtained
                                            from the “OV” function on Bloomberg, L.P. (“Bloomberg”) determined
                                            as of the day of consummation of the applicable Fundamental Transaction for pricing purposes
                                            and reflecting (A) a risk-free interest rate corresponding to the U.S. Treasury rate for
                                            a period equal to the time between the date of the public announcement of the applicable
                                            Fundamental Transaction and the Termination Date, (B) an expected volatility equal to the
                                            greater of 100% and the 100 day volatility obtained from the HVT function on Bloomberg as
                                            of the Trading Day immediately following the public announcement of the applicable Fundamental
                                            Transaction, (C) the underlying price per share used in such calculation shall be the greater
                                            of (i) the sum of the price per share being offered in cash, if any, plus the value of any
                                            non-cash consideration, if any, being offered in such Fundamental Transaction and (ii) the
                                            greater of (x) the last VWAP immediately prior to the public announcement of such Fundamental
                                            Transaction and (y) the last VWAP immediately prior to the consummation of such Fundamental
                                            Transaction and (D) a remaining option time equal to the time between the date of the public
                                            announcement of the applicable Fundamental Transaction and the Termination Date. The payment
                                            of the Black Scholes Value will be made by wire transfer of immediately available funds within
                                            five Business Days of the Holder’s election (or, if later, on the effective date of
                                            the Fundamental Transaction). The Company shall cause any successor entity in a Fundamental
                                            Transaction in which the Company is not the survivor (the “Successor Entity”)
                                            to assume in writing all of the obligations of the Company under this Warrant in accordance
                                            with the provisions of this Section 3(e) pursuant to written agreements prior to such Fundamental
                                            Transaction and shall, at the option of the Holder, deliver to the Holder in exchange for
                                            this Warrant a security of the Successor Entity evidenced by a written instrument substantially
                                            similar in form and substance to this Warrant which is exercisable for a corresponding number
                                            of shares in the share capital of such Successor Entity (or its parent entity) equivalent
                                            to the Common Shares acquirable and receivable upon exercise of this Warrant (without regard
                                            to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction,
                                            and with an exercise price which applies the exercise price hereunder to such shares (but
                                            taking into account the relative value of the Common Shares pursuant to such Fundamental
                                            Transaction and the value of such shares, such number of shares and such exercise price being
                                            for the purpose of protecting the economic value of this Warrant immediately prior to the
                                            consummation of such Fundamental Transaction). Upon the occurrence of any such Fundamental
                                            Transaction, the Successor Entity shall succeed to, and be substituted for (so that from
                                            and after the date of such Fundamental Transaction, the provisions of this Warrant referring
                                            to the “Company” shall refer instead to the Successor Entity), and may exercise
                                            every right and power of the Company and shall assume all of the obligations of the Company
                                            under this Warrant with the same effect as if such Successor Entity had been named as the
                                            Company herein.

 

    9

     

    

 

		e)	Calculations. All
                                            calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th
                                            of a share, as the case may be. For purposes of this Section 3, the number of Common Shares
                                            deemed to be issued and outstanding as of a given date shall be the sum of the number of
                                            Common Shares (excluding treasury shares, if any) issued and outstanding.

 

		f)	Notice to Holder.

 

		i.	Adjustment to Exercise
                                            Price. Whenever the Exercise Price is adjusted pursuant to any provision of this Section
                                            3, the Company shall promptly deliver to the Holder, by facsimile or email, a notice setting
                                            forth the Exercise Price after such adjustment and any resulting adjustment to the number
                                            of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.

 

		ii.	Notice to Allow Exercise by Holder. If (A) the Company shall
                                            declare a dividend (or any other distribution in whatever form) on the Common Shares, (B)
                                            the Company shall declare a special nonrecurring cash dividend on or a redemption of the
                                            Common Shares, (C) the Company shall authorize the granting to all holders of the Common
                                            Shares rights or warrants to subscribe for or purchase any shares of any class or of any
                                            rights, (D) the approval of any shareholders of the Company shall be required in connection
                                            with any reclassification of the Common Shares, any consolidation or merger to which the
                                            Company is a party, any sale or transfer of all or substantially all of the assets of the
                                            Company, or any compulsory share exchange whereby the Common Shares is converted into other
                                            securities, cash or property, or (E) the Company shall authorize the voluntary or involuntary
                                            dissolution, liquidation or winding up of the affairs of the Company, then, in each case,
                                            the Company shall cause to be delivered, by facsimile or email, to the Holder at its last
                                            facsimile number or email address as it shall appear upon the Warrant Register of the Company,
                                            at least 5 calendar days prior to the applicable record or effective date hereinafter specified,
                                            a notice stating (x) the date on which a record is to be taken for the purpose of such dividend,
                                            distribution, redemption, rights or warrants, or if a record is not to be taken, the date
                                            as of which the holders of the Common Shares of record to be entitled to such dividend, distributions,
                                            redemption, rights or warrants are to be determined or (y) the date on which such reclassification,
                                            consolidation, merger, sale, transfer or share exchange is expected to become effective or
                                            close, and the date as of which it is expected that holders of the Common Shares of record
                                            shall be entitled to exchange their Common Shares for securities, cash or other property
                                            deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange;
                                            provided that the failure to deliver such notice or any defect therein or in the delivery
                                            thereof shall not affect the validity of the corporate action required to be specified in
                                            such notice. To the extent that any notice required by this Warrant constitutes, or contains,
                                            material, non-public information regarding the Company, the Company shall simultaneously
                                            file such notice with the Commission pursuant to a Report on Form 6-K. The Holder shall remain
                                            entitled to exercise this Warrant during the period commencing on the date of such notice
                                            to the effective date of the event triggering such notice except as may otherwise be expressly
                                            set forth herein.

 

    10

     

    

 

		4	Transfer of Warrant.

 

		a)	Transferability. Subject to compliance with any applicable
                                            securities laws, this Warrant and all rights hereunder are transferable, in whole or in part,
                                            upon surrender of this Warrant at the principal office of the Company or its designated agent,
                                            together with a written assignment of this Warrant substantially in the form attached hereto
                                            duly executed by the Holder or its agent or attorney and funds sufficient to pay any transfer
                                            taxes payable upon the making of such transfer. Upon such surrender and, if required, such
                                            payment, the Company shall execute and deliver a new Warrant or Warrants in the name of the
                                            assignee or assignees, as applicable, and in the denomination or denominations specified
                                            in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing
                                            the portion of this Warrant not so assigned, and this Warrant shall promptly be cancelled.
                                            Notwithstanding anything herein to the contrary, the Holder shall not be required to physically
                                            surrender this Warrant to the Company unless the Holder has assigned this Warrant in full,
                                            in which case, the Holder shall surrender this Warrant to the Company within three (3) Trading
                                            Days of the date on which the Holder delivers an assignment form to the Company assigning
                                            this Warrant in full. The Warrant, if properly assigned in accordance herewith, may be exercised
                                            by a new holder for the purchase of Warrant Shares without having a new Warrant issued.

 

		a.	New Warrants. This Warrant may be divided or combined with
                                            other Warrants upon presentation hereof at the aforesaid office of the Company, together
                                            with a written notice specifying the names and denominations in which new Warrants are to
                                            be issued, signed by the Holder or its agent or attorney. Subject to compliance with Section
                                            4(a), as to any transfer which may be involved in such division or combination, the Company
                                            shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants
                                            to be divided or combined in accordance with such notice. All Warrants issued on transfers
                                            or exchanges shall be dated the Issue Date of this Warrant and shall be identical with this
                                            Warrant except as to the number of Warrant Shares issuable pursuant thereto.

 

		b.	Warrant Register. The Company shall register this Warrant
                                            (the “Warrant Register”), in the name of the record Holder hereof from
                                            time to time. The Company may deem and treat the registered Holder of this Warrant as the
                                            absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder,
                                            and for all other purposes, absent actual notice to the contrary.

 

		5	Miscellaneous.

 

		a)	No Rights as Shareholder Until Exercise; No Settlement in Cash.
                                            This Warrant does not entitle the Holder to any voting rights, dividends or other rights
                                            as a shareholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i),
                                            except as expressly set forth in Section 3. Without limiting the rights of a Holder to receive
                                            Warrant Shares on a “cashless exercise,” and to receive the cash payments contemplated
                                            pursuant to Sections 2(d)(i) and 2(d)(iv), in no event will the Company be required to net
                                            cash settle a Warrant exercise.

 

		b)	Loss, Theft, Destruction or Mutilation of Warrant. The Company
                                            covenants that upon receipt by the Company of evidence reasonably satisfactory to it of the
                                            loss, theft, destruction or mutilation of this Warrant or any share certificate relating
                                            to the Warrant Shares, and in case of loss, theft or destruction, of indemnity or security
                                            reasonably satisfactory to it (which, in the case of the Warrant, shall not include the posting
                                            of any bond), and upon surrender and cancellation of such Warrant or share certificate, if
                                            mutilated, the Company will make and deliver a new Warrant or share certificate of like tenor
                                            and dated as of such cancellation, in lieu of such Warrant or share certificate.

 

    11

     

    

 

		c)	Saturdays, Sundays, Holidays, etc. If the last or appointed
                                            day for the taking of any action or the expiration of any right required or granted herein
                                            shall not be a Business Day, then, such action may be taken or such right may be exercised
                                            on the next succeeding Business Day

 

		d)	Authorized Shares. The Company covenants that, during the
                                            period the Warrant is outstanding, it will reserve from its authorized and unissued Common
                                            Shares a sufficient number of Common Shares to provide for the issuance of the Warrant Shares
                                            upon the exercise of any purchase rights under this Warrant. The Company further covenants
                                            that its issuance of this Warrant shall constitute full authority to its officers who are
                                            charged with the duty of issuing the necessary Warrant Shares upon the exercise of the purchase
                                            rights under this Warrant.

 

The Company will take all
such reasonable action as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation of any
applicable law or regulation, including by maintaining an effective registration statement under the Securities Act permitting the issuance
of Warrant Shares upon exercise of this Warrant from the Initial Exercise Date until the Termination Date, or of any requirements of
the Trading Market upon which the Common Shares may be listed. The Company covenants that all Warrant Shares which may be issued upon
the exercise of the purchase rights represented by this Warrant will, upon exercise of the purchase rights represented by this Warrant
and payment for such Warrant Shares in accordance herewith, be duly authorized, validly issued, fully paid and nonassessable and free
from all taxes, liens and charges created by the Company in respect of the issue thereof (other than taxes in respect of any transfer
occurring contemporaneously with such issue).

 

Except and to the extent
as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its certificate
of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or
any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all
times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate
to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the
Company will (i) not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise immediately prior
to such increase in par value, (ii) take all such action as may be necessary or appropriate in order that the Company may validly and
legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant and (iii) use commercially reasonable efforts
to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof, as may be, necessary
to enable the Company to perform its obligations under this Warrant.

 

Before taking any action
which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the Exercise Price, the
Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory
body or bodies having jurisdiction thereof.

 

    12

     

    

 

		e)	Governing Law.
                                            This Warrant shall be governed by, and construed and enforced in accordance with, the laws
                                            of Switzerland, excluding conflict of laws principles that would cause the application of
                                            laws of any other jurisdiction. For the avoidance of doubt, matters involving the rights
                                            of shareholders, issuance of Common Shares and the validity of Common Shares shall be governed
                                            by the laws of Bermuda. Each party agrees that all legal proceedings concerning the interpretations,
                                            enforcement and defense of the transactions contemplated by this Warrant (whether brought
                                            against a party hereto or their respective affiliates, directors, officers, shareholders,
                                            partners, members, employees or agents) shall be commenced exclusively in the commercial
                                            court of Zurich. Each party hereby irrevocably submits to the exclusive jurisdiction of the
                                            commercial court of Zurich for the adjudication of any dispute hereunder or in connection
                                            herewith or with any transaction contemplated hereby or discussed herein, and hereby irrevocably
                                            waives, and agrees not to assert in any suit, action or proceeding, any claim that it is
                                            not personally subject to the jurisdiction of any such court, that such suit, action or proceeding
                                            is improper or is an inconvenient venue for such proceeding. Each party hereby irrevocably
                                            waives personal service of process and consents to process being served in any such suit,
                                            action or proceeding by mailing a copy thereof via registered or certified mail or overnight
                                            delivery (with evidence of delivery) to such party at the address in effect for notices to
                                            it under this Warrant and agrees that such service shall constitute good and sufficient service
                                            of process and notice thereof. Nothing contained herein shall be deemed to limit in any way
                                            any right to serve process in any other manner permitted by law. If either party shall commence
                                            an action, suit or proceeding to enforce any provisions of this Warrant, the prevailing party
                                            in such action, suit or proceeding shall be reimbursed by the other party for their reasonable
                                            attorneys’ fees and other costs and expenses incurred with the investigation, preparation
                                            and prosecution of such action or proceeding.

 

		f)	Restrictions.
                                            The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant,
                                            if not registered and the Holder does not utilize cashless exercise, will have restrictions
                                            upon resale imposed by state and federal securities laws.

 

		g)	Nonwaiver and Expenses.
                                            No course of dealing or any delay or failure to exercise any right hereunder on the part
                                            of Holder shall operate as a waiver of such right or otherwise prejudice the Holder’s
                                            rights, powers or remedies. Without limiting any other provision of this Warrant, if the
                                            Company willfully and knowingly fails to comply with any provision of this Warrant, which
                                            results in any material damages to the Holder, the Company shall pay to the Holder such amounts
                                            as shall be sufficient to cover any costs and expenses including, but not limited to, reasonable
                                            attorneys’ fees, including those of appellate proceedings, incurred by the Holder in
                                            collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers
                                            or remedies hereunder.

 

		h)	Notices. Any
                                            and all notices or other communications or deliveries to be provided by the Holders hereunder
                                            including, without limitation, any Notice of Exercise, shall be in writing and delivered
                                            personally, by e-mail, or sent by a nationally recognized overnight courier service, addressed
                                            to the Company, at Clarendon House, 2 Church Street, Hamilton HM 11, Bermuda, Attention:
                                            CEO, email address: [**], or such other email address or address as the Company may specify
                                            for such purposes by notice to the Holders. Any and all notices or other communications or
                                            deliveries to be provided by the Company hereunder shall be in writing and delivered personally,
                                            by facsimile or e-mail, or sent by a overnight courier service addressed to each Holder at
                                            the facsimile number, e-mail address or address of such Holder appearing on the books of
                                            the Company. Any notice or other communication or deliveries hereunder shall be deemed given
                                            and effective on the earliest of (i) the date of transmission, if such notice or communication
                                            is delivered via facsimile at the facsimile number or via e-mail at the e-mail address set
                                            forth in this Section prior to 5 p.m. (Zurich time) on any date, (ii) the next Trading Day
                                            after the date of transmission, if such notice or communication is delivered via facsimile
                                            at the facsimile number or via e-mail at the e-mail address set forth in this Section on
                                            a day that is not a Trading Day or later than 5 p.m. (Zurich time) on any Trading Day, (iii)
                                            the second Trading Day following the date of mailing, if sent by overnight courier service,
                                            or (iv) upon actual receipt by the party to whom such notice is required to be given. To
                                            the extent that any notice provided hereunder constitutes, or contains, material, non-public
                                            information regarding the Company or any Subsidiaries, the Company shall simultaneously file
                                            such notice with the Commission pursuant to a Report on Form 6-K.

 

    13

     

    

 

		i)	Limitation of Liability.
                                            No provision hereof, in the absence of any affirmative action by the Holder to exercise this
                                            Warrant to purchase Warrant Shares, and no enumeration herein of the rights or privileges
                                            of the Holder, shall give rise to any liability of the Holder for the purchase price of any
                                            Common Share or as a shareholder of the Company, whether such liability is asserted by the
                                            Company or by creditors of the Company.

 

		j)	Remedies. The
                                            Holder, in addition to being entitled to exercise all rights granted by law, including recovery
                                            of damages, will be entitled to specific performance of its rights under this Warrant. The
                                            Company agrees that monetary damages would not be adequate compensation for any loss incurred
                                            by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive
                                            and not to assert the defense in any action for specific performance that a remedy at law
                                            would be adequate.

 

		k)	Successors and Assigns.
                                            Subject to applicable securities laws, this Warrant and the rights and obligations evidenced
                                            hereby shall inure to the benefit of and be binding upon the successors and permitted assigns
                                            of the Company and the successors and permitted assigns of Holder. The provisions of this
                                            Warrant are intended to be for the benefit of any Holder from time to time of this Warrant
                                            and shall be enforceable by the Holder or holder of Warrant Shares.

 

		l)	Amendment. This
                                            Warrant may be modified or amended or the provisions hereof waived with the written consent
                                            of the Company, on the one hand, and the Holder or the beneficial owner of this Warrant,
                                            on the other hand.

 

		m)	Severability.
                                            Wherever possible, each provision of this Warrant shall be interpreted in such manner as
                                            to be effective and valid under applicable law, but if any provision of this Warrant shall
                                            be prohibited by or invalid under applicable law, such provision shall be ineffective to
                                            the extent of such prohibition or invalidity, without invalidating the remainder of such
                                            provisions or the remaining provisions of this Warrant.

 

		n)	Headings. The headings used in this Warrant are for the
                                            convenience of reference only and shall not, for any purpose, be deemed a part of this Warrant.

 

    14

     

    

 

IN
WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above
indicated.

 

	ALTAMIRA THERAPEUTICS LTD.	 
	 	 	 
	By:	 	 
	Name: 	                  	 
	Title:	 	 

 

     

     

    

 

EXHIBIT A

 

NOTICE OF EXERCISE

 

TO: ALTAMIRA THERAPEUTICS LTD.

 

(1) The undersigned hereby
elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only if exercised in full),
and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.

 

(2) Payment shall take
the form of (check applicable box):

 

☐ in CHF; or

 

☐
if permitted, the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in
subsection 2(c), to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless
exercise procedure set forth in subsection 2(c).

 

(3) Please issue said Warrant
Shares in the name of the undersigned or in such other name as is specified below:

 

	 	 

 

The Warrant Shares shall
be delivered to the following DWAC Account Number:

 

	 	 

 

[SIGNATURE OF HOLDER]

 

Name of Investing Entity:

 

	 	 

 

Signature of Authorized Signatory of Investing
Entity:

 

	 	 

 

Name of Authorized Signatory:

 

	 	 

 

Title of Authorized Signatory:

 

	 	 

 

Date:

 

	 	 

 

     

     

    

 

EXHIBIT B

 

ASSIGNMENT FORM

 

(To assign the foregoing
Warrant, execute this form and supply required information. Do not use this form to purchase shares.)

 

FOR VALUE RECEIVED, the
foregoing Warrant and all rights evidenced thereby are hereby assigned to

 

	Name:	 	 
	 	 	 
	 	(Please Print)	 
	 	 	 
	Address:	 	 
	 	 	 
	 	(Please Print)	 
	 	 	 
	Phone Number:	 	 
	 	 	 
	Email Address:	 	 

 

	Dated:____________ _____, ______	 
	 	 
	Holder’s signature:	 
	 	 
	 	 
	Holder’s address:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00348-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00348-of-00352.parquet"}]]